Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414975 | 0.98 | KDM2B (0.39) | KDM2BAXLTYRO3MERTKHRH3 | |
| SCHEMBL5422019 | 0.91 | HRH3 (0.45) | AXLTYRO3MERTKHRH3KCNH2 | |
| SCHEMBL5412679 | 0.87 | HRH3 (0.47) | AXLTYRO3MERTKHRH3KCNH2 | |
| SCHEMBL5408010 | 0.85 | AXL (0.40) | AXLTYRO3MERTKROCK2CCR2 | |
| SCHEMBL5417742 | 0.85 | AXL (0.46) | AXLTYRO3MERTKHRH3KCNH2 | |
| SCHEMBL5417735 | 0.85 | AXL (0.46) | AXLTYRO3MERTKHRH3KCNH2 | |
| SCHEMBL5425243 | 0.85 | AXL (0.46) | AXLTYRO3MERTKHRH3KCNH2 | |
| SCHEMBL5410001 | 0.83 | AXL (0.38) | KDM2BAXLTYRO3MERTKHRH3 | |
| SCHEMBL5410006 | 0.83 | AXL (0.38) | KDM2BAXLTYRO3MERTKHRH3 | |
| SCHEMBL5410008 | 0.83 | AXL (0.38) | KDM2BAXLTYRO3MERTKHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | KDM2B 2292/4885AXL 1805/4885TYRO3 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.